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Introduction
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neurone disease (MND). It is characterised by relentless degeneration of vulnerable neuronal cell populations, principally upper and lower motor neurones of the precentral gyrus, brainstem and spinal cord. This results in muscle weakness, atrophy and spasticity, leading to widespread paralysis that culminates in respiratory failure, typically within 2 to 3 years from the point of diagnosis 1 . ALS has an incidence of approximately 2 individuals per 100,000 2 with a slight male preponderance 3 . Pathologically, classical ALS is characterised by motor neurone loss with ubiquitylated neuronal cytoplasmic inclusions of TDP-43 4 .
Approximately 5-10% of ALS cases are classified as familial (fALS), where ALS is documented in a first or second degree relative, whereas the remainder are deemed sporadic (sALS), appearing to occur without a relevant family history 5 . The first ALS gene found to cause fALS was SOD1 in 1993 6 and since the discovery that TARDBP mutations can cause ALS in 2006 7 , the number of known of ALS-causing genes has grown rapidly to over 20 (alsod.iop.kcl.ac.uk). We now know the genetic aetiology of approximately two thirds of familial cases and 11% of sporadic cases 8 , following the identification of the GGGGCC repeat expansion in the C9ORF72 gene in 40-50% of fALS cases 9, 10 .
Several mutations have been identified within the optineurin (OPTN) gene on chromosome 10 that are reported to cause ALS, first in Japanese, then in European and Scandinavian populations [11] [12] [13] [14] [15] [16] . However, a number of studies have failed to find OPTN mutations in ALS patients [17] [18] [19] [20] , suggesting this to be a rare occurrence.
OPTN mutations have long been known to cause the neurodegenerative disorder primary
open angle glaucoma (POAG) 21 , and, more recently have been associated with Paget's disease of bone 22 . The OPTN gene spans 37kb on chromosome 10, has 3 non-coding exons and 13 exons that encode a 577 amino acid, 67kDa protein which functions as a dimer 23 . It shares a 53% similarity with the NFB essential modulator (NEMO) at both the primary sequence and domain organisation levels 24 . It has two coiled-coils, a ubiquitin binding domain, a ubiquitin-binding zinc finger, a microtubule associated protein 1 light chain 3 (LC3)-interacting motif and a zinc finger 25 . It is a ubiquitously expressed cytosolic protein that primarily localises to the perinuclear region of the cell where it associates with the Golgi apparatus and is known to interact with a plethora of molecules including the type 1a metabotropic glutamate receptor and huntingtin 26, 27 . It is involved in multiple cellular functions and signalling pathways, including down regulation of the NFB pathway, protection against oxidative stress-induced apoptosis, membrane trafficking and Golgi organisation, protein secretion and regulation of mitotic progression 23 .
The aim of this study was to establish the contribution of OPTN mutations as a genetic cause of fALS and sALS in a Caucasian cohort from the North of England. On finding a case with simultaneous OPTN and C9ORF72 mutations, we proceeded to characterise the neuropathology, and elucidated the degree of optineurin incorporation into the TDP-43-negative ubiquitylated neuronal cytoplasmic inclusions of C9ORF72-ALS. were screened using previously published primer sequences (Eurofins MWG Operon, Germany) 11 . PCR reactions were performed in a total volume of 20µl as described primary antibody used at 1:400 dilution) and optineurin was performed on adjacent sections of spinal cord from the proband. Immunohistochemistry for p62, TDP-43 and poly-GA dipeptide repeat was performed as described elsewhere 31, 34 . We are grateful to Prof Dieter
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Edbauer of the German Centre for Neurodegenerative Diseases, Munich for the kind gift of the poly-GA antibody.
Adjacent sections of spinal cord from
Results
Mutation Screening
Screening analysis of the 16 exons of OPTN, including intron/exon boundaries, in 42 fALS and 47 sALS index cases identified two non-synonymous substitutions in exons 5 and 10
and one novel intronic substitution. In addition, sequencing also identified seventeen previously identified single nucleotide polymorphisms (SNPs) including two upstream of the coding region, eleven intronic variants as well as two 5'UTR and two synonymous substitutions (Table 1) .
A heterozygous c.964G>A (p.E322K) missense mutation (rs523747) was identified in exon 10 of one fALS individual ( Figure 1a ; the proband), which was absent from 375 unrelated neurologically normal control subjects (Figure 1b) . The negatively charged glutamic acid, which is substituted to a positively charged lysine in the coiled coil II domain, is highly conserved across a diverse range of species, including mammals, chicken, zebrafish and treefrog ( Figure 2 ). The p.E322K mutation is described as a missense variant by Ensembl and is predicted to be pathogenic according to Polyphen (probably damaging) and SIFT (deleterious; Ensembl predicted consequences; Interestingly, the proband was subsequently found to carry a hexanucleotide repeat expansion in C9ORF72. Southern blotting on DNA extracted from venous blood, cerebellum and frontal cortex revealed somatic heterogeneity, but in all tissues repeat length was >600
units.
The heterozygous non-synonymous c.293T>A (p.M98K) change in exon 5 (rs11258194) was detected in six fALS cases and one sALS patient. The methionine to lysine substitution occurs within the binding site of Rab8 and is situated in the coiled coil I domain of optineurin.
This nucleotide change was also found in 4.15% of controls screened, a frequency similar to that of 4.5% seen in the 1000 Genomes Phase 1 data for Europe. Consistent with the presence of the allele within the normal population, in silico analysis using PolyPhen and SIFT suggests the alteration is non-pathogenic.
The novel intronic polymorphism was not predicted to alter any splice sites according to Flybase analysis. Of the other SNPs identified, the frequencies of these within our ALS cohort were comparable to those reported within the 1000 Genomes Project Phase1.
Clinical Phenotype
The proband (II:5) was a Caucasian female who in her past had suffered with migraine, a ruptured ovarian cyst and had undergone a hysterectomy for menorrhagia. 
Neuropathology
Macroscopically the brain and spinal cord were unremarkable externally and on slicing.
Microscopy revealed classical ALS neuropathology ( Figure 3 ): For the motor system, the spinal cord and medulla showed depleted numbers of lower motor neurones, whilst the motor cortex showed mild (predominantly layer II) vacuolation with negligible neuronal loss.
Immunohistochemistry revealed glial and neuronal (both skein-like and compact) ubiquitylated cytoplasmic inclusions in residual motor neurones that were identified on p62
and TDP-43 immunohistochemistry. Long, pyramidal tract degeneration was highlighted by pallor of myelin staining in the lateral tracts of the spinal cord. Immunohistochemistry for FUS showed normal, predominantly nuclear staining.
Superimposed on this classical ALS neuropathology, was the extra-motor pathology that is the hallmark of C9ORF72-ALS. Thus, in the hippocampus, there were multiple ubiquitylated (p62-positive, TDP-43-negative; henceforth TDP-43-negative inclusions). These were also seen in the frontal neocortex and cerebellum, in common with other C9ORF72-ALS cases from our collection 35 .
Immunohistochemistry for optineurin in neurologically healthy control tissue revealed expression in neuronal cytoplasm (including dendritic processes) and neuropil with a small amount of glial (predominantly astrocytic) expression (figure 4a). Spinal cord from sporadic ALS cases revealed a similar pattern of staining (figure 4b), with the additional labelling of neuronal cytoplasmic inclusions (both compact and skein-like) as described by previous authors 11, 36 .
Optineurin immunopositivity in neuronal cytoplasmic inclusions in the spinal cord anterior horn was also present in the index case (figure 4c). Immunohistochemistry for ubiquitin or optineurin on adjacent sections revealed neurones that either had cytoplasmic inclusions positive for both optineurin and ubiquitin; or had no inclusions on either preparation (supplementary figure 1) . Interestingly, there was also labelling of some of the TDP-43 negative inclusions, most readily apparent in the CA3-4 subfield of the hippocampus. These were much harder to discern in the cerebellum, but were present (figures 4e, f). Optineurin immunohistochemistry also labelled neuronal cytoplasmic inclusions in the cases of ALS due to mutations of FUS and SOD1. This was as has been described previously for
FUS mutations
37
. In contrast with the existing literature 11 , optineurin-positive inclusions were distinct from hyaline conglomerate inclusions, which were unlabelled.
Discussion
In this study, we have screened a cohort of cases of ALS from the North of England, and identified a p.E322K mutation in OPTN. The amino acid substitution is predicted to be pathogenic and has been previously reported as a cause of primary open angle glaucoma (POAG) 23 . The amino acid is highly conserved throughout the species and was not found in 750 chromosomes screened in age-matched controls from the same geographical region;
only one other variant has been identified within a screen of 1004 European chromosomes, establishing it as a very rare variant, which we proposed to be associated with ALS. The individual was subsequently shown to carry a hexanucleotide expansion of C9ORF72.
Reports of oligogenic inheritance in ALS are increasingly being published; mutations in C9ORF72 and SOD1, FUS, TARDBP, VAPB and other rarer variants have been identified, as well as mutations in angiogenin (ANG) along with SOD1, FUS, TARDBP and VAPB mutations and other double rare variants [38] [39] [40] [41] . The presence of additional genetic variants has been demonstrated to be associated with an earlier age of onset, suggesting additive or synergistic effects, in disease pathogenesis 40 .
The p.E322K mutation described here is rare in the UK and European population and high levels of conservation are observed in multiple different species. However, despite this mutation having been associated with POAG, the pathogenicity of this OPTN mutation in relation to ALS needs to confirmed experimentally, particularly given that this patient was subsequently shown to carry a hexanucleotide repeat expansion of C9ORF72 . Table 2 In silico analysis summary of mutation effects. (arrows) in extra motor regions, e.g. the hippocampus (e, bar=50m) and the cerebellum (f, bar=50m). 
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